Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 33 n° 244

Posts Tagged ‘puma’

Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference 2019

Posted by fidest press agency su venerdì, 10 maggio 2019

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 3:00 p.m. PDT on Wednesday, May 15, at the Bank of America Merrill Lynch Health Care Conference 2019. The conference will be held at Encore at the Wynn in Las Vegas.A live webcast of the presentation will be available on the Company’s website at http://www.pumabiotechnology.com. The presentation will be archived on the website and available for 30 days.Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to three drug candidates — PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in July 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. NERLYNX was granted marketing authorization by the European Commission in September 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Puma Biotechnology to Present at Cowen’s Annual Health Care Conference

Posted by fidest press agency su sabato, 9 marzo 2019

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 10:00 a.m. EDT on Tuesday, March 12 at the Cowen and Company 39th Annual Health Care Conference. The conference will be held at the Boston Marriott Copley Place.A live webcast of the presentation will be available on the Company’s website at http://www.pumabiotechnology.com. The presentation will be archived on the website and available for 30 days.Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The Company in-licenses the global development and commercialization rights to three drug candidates — PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in July 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. NERLYNX was granted marketing authorization by the European Commission for the extended adjuvant treatment of hormone receptor-positive HER2-positive early stage breast cancer in September 2018. NERLYNX is a registered trademark of Puma Biotechnology, Inc. Further information about Puma Biotechnology may be found at http://www.pumabiotechnology.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Puma Biotechnology to Present at Credit Suisse Healthcare Conference

Posted by fidest press agency su venerdì, 9 novembre 2018

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 9:10 a.m. MST (8:10 a.m. PST, 11:10 a.m. EST) on Wednesday, November 14, at the Credit Suisse 27th Annual Healthcare Conference. The conference will be held at The Phoenician Resort in Scottsdale, Arizona.A live webcast of the presentation will be available on the Company’s website at http://www.pumabiotechnology.com. The presentation will be archived on the website and available for 30 days.
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The Company in-licenses the global development and commercialization rights to three drug candidates — PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in July 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. NERLYNX was granted marketing authorization by the European Commission for the extended adjuvant treatment of hormone receptor-positive HER2-positive early stage breast cancer in September 2018. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

Puma Biotechnology to Present at Jefferies Global Healthcare Conference

Posted by fidest press agency su sabato, 2 giugno 2018

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 11:00 a.m. EDT on Thursday, June 7, at the Jefferies 2018 Healthcare Conference.A live webcast of the presentation will be available on the Company’s website at http://www.pumabiotechnology.com. The presentation will be archived on the website and available for 30 days.
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The Company in-licenses the global development and commercialization rights to three drug candidates — PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in July 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »